Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS)
- PMID: 15077311
- DOI: 10.1002/art.20146
Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS)
Abstract
Objective: There is no effective treatment for patients with primary Sjögren's syndrome (SS). Since tumor necrosis factor alpha (TNF alpha) could be a key element in the pathogenesis of primary SS, we conducted a multicenter, randomized, double-blind, placebo-controlled trial to evaluate the effect of infliximab in primary SS.
Methods: A total of 103 patients with primary SS were randomly assigned to receive infliximab infusions (5 mg/kg) or placebo at weeks 0, 2, and 6 and were followed up for 22 weeks. All patients fulfilled the new American-European Consensus Group criteria for SS and had active disease as assessed by values >50 mm on 2 of 3 visual analog scales (VAS) (0-100 mm) that evaluated joint pain, fatigue, and buccal, ocular, skin, vaginal, or bronchial dryness. A favorable overall response was defined as the patient having > or =30% improvement between weeks 0 and 10 in the values on 2 of the 3 VAS. Secondary end points were values on each VAS separately, the number of tender and swollen joints, the basal salivary flow rate, results of the Schirmer test for lacrimal gland function, the focus score on labial salivary gland biopsy, the level of C-reactive protein, and the erythrocyte sedimentation rate evaluated at weeks 0, 10, and 22, as well as quality of life evaluated by use of the generic Short Form 36 questionnaire administered at weeks 0, 10, and 22.
Results: At week 10, 26.5% of patients receiving placebo and 27.8% of patients treated with infliximab had a favorable overall response (P = 0.89), and at week 22, 20.4% of the placebo group and 16.7% of the infliximab group had a favorable response (P = 0.62). In addition, the 2 groups did not differ in any of the secondary end points over the 22 weeks of the trial. Severe adverse events reported in the infliximab group did not differ from those observed in previous studies.
Conclusion: This randomized, double-blind, placebo-controlled study of an anti-TNF agent did not show any evidence of efficacy of infliximab in primary SS.
Comment in
-
Infliximab and primary Sjogren's syndrome: comment on the article by Mariette et al.Arthritis Rheum. 2004 Dec;50(12):4077; author reply 4077-8. doi: 10.1002/art.20803. Arthritis Rheum. 2004. PMID: 15593208 No abstract available.
Similar articles
-
Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial.Arthritis Rheum. 2010 Apr;62(4):960-8. doi: 10.1002/art.27314. Arthritis Rheum. 2010. PMID: 20131246 Clinical Trial.
-
Etanercept in Sjögren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial.Arthritis Rheum. 2004 Jul;50(7):2240-5. doi: 10.1002/art.20299. Arthritis Rheum. 2004. PMID: 15248223 Clinical Trial.
-
A pilot study to test the efficacy of oral administration of interferon-alpha lozenges to patients with Sjögren's syndrome.Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003 Jan;95(1):38-44. doi: 10.1067/moe.2003.30. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003. PMID: 12539025 Clinical Trial.
-
A review of infliximab use in ulcerative colitis.Clin Ther. 2008 Feb;30(2):223-30. doi: 10.1016/j.clinthera.2008.02.014. Clin Ther. 2008. PMID: 18343261 Review.
-
Treatment with infliximab plus methotrexate improves anemia in patients with rheumatoid arthritis independent of improvement in other clinical outcome measures-a pooled analysis from three large, multicenter, double-blind, randomized clinical trials.Semin Arthritis Rheum. 2009 Oct;39(2):123-31. doi: 10.1016/j.semarthrit.2008.08.002. Epub 2008 Sep 27. Semin Arthritis Rheum. 2009. PMID: 18823645 Review.
Cited by
-
Emerging biologic frontiers for Sjogren's syndrome: Unveiling novel approaches with emphasis on extra glandular pathology.Front Pharmacol. 2024 May 17;15:1377055. doi: 10.3389/fphar.2024.1377055. eCollection 2024. Front Pharmacol. 2024. PMID: 38828450 Free PMC article. Review.
-
Investigative biological therapies for primary Sjögren's syndrome.Arch Med Sci. 2020 Jul 15;20(2):506-516. doi: 10.5114/aoms.2020.97288. eCollection 2024. Arch Med Sci. 2020. PMID: 38757038 Free PMC article.
-
Chemokines and lymphocyte homing in Sjögren's syndrome.Front Immunol. 2024 Apr 26;15:1345381. doi: 10.3389/fimmu.2024.1345381. eCollection 2024. Front Immunol. 2024. PMID: 38736890 Free PMC article. Review.
-
Manifestations and management of Sjögren's disease.Arthritis Res Ther. 2024 Feb 8;26(1):43. doi: 10.1186/s13075-024-03262-4. Arthritis Res Ther. 2024. PMID: 38331820 Free PMC article. Review.
-
Association of endometriosis with Sjögren's syndrome: Genetic insights (Review).Int J Mol Med. 2024 Feb;53(2):20. doi: 10.3892/ijmm.2024.5344. Epub 2024 Jan 8. Int J Mol Med. 2024. PMID: 38186322 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials